home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Development of Type 2 Diabetes Mellitus Medications: State of the Art Development Issues and Benefit/Risk Assessment

 
  October 08, 2011  
     
 
Omni Shoreham Hotel , Washington, DC, USA
Nov 29 2011 8:00AM - Dec 1 2011 4:00PM


CALL FOR ABSTRACTS

All abstracts must be received by October 28, 2011 

Member Early-bird  Opportunity on or before November 9, 2011
Available on Nondiscount Member Fee only

Join Industry Experts and Regulators to Explore New Solutions and Approaches to Developing Safe and Effective Type 2 Diabetes Mellitus Medications
The development of Type 2 diabetic (T2DM) medications has been significantly impacted by recent data suggesting possible increases in cardiovascular (CV) risk associated with:
• Use of tight glucose control with insulin
• Certain oral drugs used to treat T2DM
• Complexity of properly analyzing benefit and risk
In 2008, the Division of Metabolism and Endocrinology Products of the US Food and Drug Administration (FDA) adopted a new regulatory guidance suggesting that all new T2DM drugs demonstrate CV safety in appropriately designed and powered outcome studies. The EMEA released its draft guidance in 2010. Thus, the approach to the development of medications to treat type 2 diabetes mellitus is undergoing active discussion and the Benefit to Risk analysis is evolving.

 
 
Organized by: DIA
Invited Speakers: See website for speaker information
 
Deadline for Abstracts: 10/28/2011
 
Registration: For further information, contact
Carrie Dunn, Program Developer
Phone +1.215.442.6181
Fax +1.215.293.5987
E-mail: carrie.dunn@diahome.org
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.